Pharmacogenetics and immunosuppressive drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10286424" target="_blank" >RIV/00216208:11110/14:10286424 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1586/17512433.2014.966811" target="_blank" >http://dx.doi.org/10.1586/17512433.2014.966811</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1586/17512433.2014.966811" target="_blank" >10.1586/17512433.2014.966811</a>

Result language
angličtina
Original language name
Pharmacogenetics and immunosuppressive drugs
Original language description
Several candidate genes have been proposed as potential biomarkers for altered pharmacodynamics or pharmacokinetics of immunosuppressive drugs. However, there is usually only limited clinical evidence substantiating the implementation of biomarkers intoclinical practice. Testing for thiopurine-S-methyltransferase polymorphisms has been put into routine clinical use quite widely, while the other pharmacogenetic tests are much less frequently used. Relatively good evidence appeared for tacrolimus-relatedbiomarkers; thus, their utilization may be envisaged in the near future. Although the biomarkers related to mycophenolate, sirolimus or other drugs in the therapeutic class may be promising, further research is necessary to provide more robust evidence.The present review focuses on immunosuppressive drugs, excluding biological treatment.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)